Pharma firepower, M&A surge last year bode well for dealmaking prospects in 2024: EY
Fierce Pharma
JANUARY 8, 2024
Morgan Healthcare Conference. | The late surge of activity in 2023 also bodes well for a 2024 uptick, the group said. Biopharma companies looking to maximize the visibility of their M&A activity often reveal deals during the J.P.
Let's personalize your content